RNA nanostructures for targeted drug delivery and imaging

RNA Biol. 2024 Jan;21(1):1-19. doi: 10.1080/15476286.2024.2328440. Epub 2024 Mar 31.

Abstract

The RNA molecule plays a pivotal role in many biological processes by relaying genetic information, regulating gene expression, and serving as molecular machines and catalyzers. This inherent versatility of RNA has fueled significant advancements in the field of RNA nanotechnology, driving the engineering of complex nanoscale architectures toward biomedical applications, including targeted drug delivery and bioimaging. RNA polymers, serving as building blocks, offer programmability and predictability of Watson-Crick base pairing, as well as non-canonical base pairing, for the construction of nanostructures with high precision and stoichiometry. Leveraging the ease of chemical modifications to protect the RNA from degradation, researchers have developed highly functional and biocompatible RNA architectures and integrated them into preclinical studies for the delivery of payloads and imaging agents. This review offers an educational introduction to the use of RNA as a biopolymer in the design of multifunctional nanostructures applied to targeted delivery in vivo, summarizing physical and biological barriers along with strategies to overcome them. Furthermore, we highlight the most recent progress in the development of both small and larger RNA nanostructures, with a particular focus on imaging reagents and targeted cancer therapeutics in pre-clinical models and provide insights into the prospects of this rapidly evolving field.

Keywords: RNA nanostructures; RNA therapeutics; aptamers; bioconjugation; bioimaging; cancer; personalized nanomedicine; targeted drug delivery; tumour targeting.

Publication types

  • Review

MeSH terms

  • DNA / chemistry
  • Humans
  • Nanostructures* / chemistry
  • Nanotechnology / methods
  • Neoplasms* / diagnostic imaging
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • RNA / genetics

Substances

  • RNA
  • DNA

Grants and funding

L. T. was supported by the Novo Nordisk Foundation [NNF23OC0081177, RNA-META] and the Danish National Research Foundation (Centre for Cellular Signal Patterns, DNRF135). M.O. was funded, in part, by grant DNRF135 and by the Novo Nordisk Foundation [NNF23OC0082848].